HOT NEWS
Oct 29,2025
As reported by OncLive®, October 2025: FDA Grants Fast Track Designation to NBM-BMX for Metastatic Uveal Melanoma
TAIPEI and San Diego, USA – NovelWise Pharmaceutical Corporation today announced that its investigational agent NBM-BMX, a selective HDAC8 inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic uveal melanoma, a rare and aggressive eye cancer with limited therapeutic options.
Jul 30,2025
Novelwise Pharmaceuticals Announces FDA“May Proceed”Clearance for Phase Ib/II Trial of NBM-BMX in Metastatic Uveal Melanoma
Taipei, July 30, 2025 —— Novelwise Pharmaceuticals today announced that its investigational cancer therapy NBM-BMX has been deemed may proceed by the United States Food and Drug Administration (US FDA).
Aug 25,2025
Novelwise Pharmaceuticals Announces Collaboration with U.S. Patient Advocacy Group A Cure In Sight (ACIS) to Advance Ocular Melanoma Research
Novelwise Pharmaceuticals is honored to announce its collaboration with the U.S. patient advocacy organization A Cure In Sight (ACIS) in August 2025.
About Us
Novelwise Pharmaceutical Corporation was formerly the New Drug Research and Development Department of NatureWise Biotech Medicals Corporation. We have over 20 years of experience in new drug development, including basic research, clinical translation, and strategic planning. As our new drug development projects reached significant milestones, the RD Department was established as a separate entity in 2023 to expedite its progress.
